PLK1 antibody (pThr210)

Catalog No. ABIN967616

The Mouse Monoclonal anti-PLK1 antibody has been validated for WB. It is suitable to detect PLK1 in samples from Human and Mouse. There are 3+ publications available.

Quick Overview for PLK1 antibody (pThr210) (ABIN967616)

Target: PLK1 (Polo-Like Kinase 1 (PLK1))

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This PLK1 antibody is un-conjugated

Application: Western Blotting (WB)

Clone: K50-483

Product Details anti-PLK1 Antibody

Binding Specificity: pThr210

Brand: BD Pharmingen™

Cross-Reactivity (Details): Predicted: Mouse

Characteristics: 1. Please refer to us for technical protocols.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Phosphorylated Human PLK1 Peptide

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

References for anti-PLK1 antibody (ABIN967616)

Peter, Gleixner, Cerny-Reiterer, Herrmann, Winter, Hadzijusufovic, Ferenc, Schuch, Mirkina, Horny, Pickl, Müllauer, Willmann, Valent: "Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536." in: Haematologica, Vol. 96, Issue 5, pp. 672-80, (2011) (PubMed).

Yamashiro, Yamakita, Totsukawa, Goto, Kaibuchi, Ito, Hartshorne, Matsumura: "Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1." in: Developmental cell, Vol. 14, Issue 5, pp. 787-97, (2008) (PubMed).

Ando, Ozaki, Yamamoto, Furuya, Hosoda, Hayashi, Fukuzawa, Nakagawara: "Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation." in: The Journal of biological chemistry, Vol. 279, Issue 24, pp. 25549-61, (2004) (PubMed).

Target Details for PLK1

Target: PLK1 (Polo-Like Kinase 1 (PLK1))

Alternative Name: PLK1

Background: Polo-like kinase (PLK1) is a serine/threonine kinase with structural similarities to Drosophila's Polo kinase and the Cdc5p of Saccharomyces cerevisiae. Like its invertebrate counterparts, PLK1 activity is required for DNA synthesis and is regulated throughout the cell cycle. Furthermore, PLK1 is highly expressed in primary tumors. It associates with the mitotic spindle during mitosis suggesting that, in addition to its role during S phase, PLK1 may play a role during chromosome segregation. This is consistent with its potential role in cancer development. Threonine 210 (T210) is one of the major phoshorylation sites in activated PLK1 obtained from human mitotic cells.
The K50-483 monoclonal antibody recognizes the phosphorylated T210 of human PLK1.

Molecular Weight: 68 kDa

Pathways: Cell Division Cycle, M Phase